Investigational ultra-long-acting insulin degludec reduces rates of nocturnal hypoglycaemia in type 2 diabetes patients versus insulin glargine...

Ultra-long-acting insulin degludec , (see structure) an investigational insulin being developed by Novo Nordisk, significantly reduc...